cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Neurocrine Biosciences Inc
65 own
13 watching
Current Price
$140.9
$2.19
(1.58%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
9,167.92M
52-Week High
52-Week High
157.98000
52-Week Low
52-Week Low
110.95000
Average Volume
Average Volume
1.12M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
20.4735
iconMarket Capitalization9,167.92M
icon52-Week High157.98000
icon52-Week Low110.95000
iconAverage Volume1.12M
iconDividend Yield--
iconP/E Ratio20.4735
What does the Neurocrine Biosciences Inc do?
Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States and internationally. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2) used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trials used for women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trials used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease. It is also developing NBI-640756 that is in Phase I clinical trials used for the treatment of essential tremor; and NBI-74788, which is in Phase I clinical trials used for the treatment of classic congenital adrenal hyperplasia. In addition, the company's research programs comprise VMAT2 Inhibitors for movement disorders, bipolar disorders, and schizophrenia; and G Protein-Coupled Receptors and Ion Channels for epilepsy, essential tremor, pain, and other Indications. It has collaborations with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson's disease. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Read More
How much money does Neurocrine Biosciences Inc make?
News & Events about Neurocrine Biosciences Inc.
PR Newswire
1 year ago
Neurocrine Biosciences Supports the Mental Health Community During Tardive Dyskinesia Awareness Week Neurocrine Biosciences Supports the Mental Health Community During Tardive Dyskinesia Awareness Week PR Newswire SAN DIEGO, May 1, 2023 Approximately 600,000 people in the United States live with...
Ticker Report
1 year ago
Neurocrine Biosciences, Inc. (NASDAQ:NBIX Get Rating) insider Eiry Roberts sold 14,400 shares of the stock in a transaction dated Monday, April 24th. The shares were sold at an average price of $103.48, for a total transaction of $1,490,112.00. Following the completion of the transaction, ...
TipRanks Financial Blog
1 year ago
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cytokinetics (CYTK Research Report) and Neurocri... Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cytokinetics (CYTK Research Report) and Neurocrine...
Benzinga
1 year ago
Latest Ratings for NBIX DateFirmActionFromTo Mar 2022Piper SandlerDowngradesOverweightNeutral Feb 2022Goldman SachsUpgradesNeutralBuy Feb 2022Morgan StanleyMaintainsEqual-Weight View More Analyst Ratings for NBIX View the Latest Analyst Ratings read more...
PR Newswire
1 year ago
Neurocrine Biosciences Presents Data on Improvements Over Time with Long-Term Use of INGREZZA (valbenazine) Capsules in Older and Elderly Patients at the American Association for Geriatric Psychiatry 2023 Annual Meeting Neurocrine Biosciences Presents Data on Improvements Over Time with Long-Term...
Frequently Asked Questions
Frequently Asked Questions
What is Neurocrine Biosciences Inc share price today?
plus_minus_icon
Can Indians buy Neurocrine Biosciences Inc shares?
plus_minus_icon
How can I buy Neurocrine Biosciences Inc shares from India?
plus_minus_icon
Can Fractional shares of Neurocrine Biosciences Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Neurocrine Biosciences Inc stocks?
plus_minus_icon
What is today’s traded volume of Neurocrine Biosciences Inc?
plus_minus_icon
What is today’s market capitalisation of Neurocrine Biosciences Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Neurocrine Biosciences Inc?
plus_minus_icon
What percentage is Neurocrine Biosciences Inc down from its 52-Week High?
plus_minus_icon
What percentage is Neurocrine Biosciences Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$140.9
$2.19
(1.58%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
LivaNova PLC
LivaNova PLC
$46.66
$-1.38 (-2.87 %)
Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc.
$94.87
$12.31 (14.91 %)
Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc.
$341.75
$-2.63 (-0.76 %)
Bio-Techne Corp.
Bio-Techne Corp.
$73.31
$-1.88 (-2.50 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
LivaNova PLC
LivaNova PLC
$46.66
$-1.38 (-2.87 %)
Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc.
$94.87
$12.31 (14.91 %)
Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc.
$341.75
$-2.63 (-0.76 %)
Bio-Techne Corp.
Bio-Techne Corp.
$73.31
$-1.88 (-2.50 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00